MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)Business Wire • Monday
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 CongressBusiness Wire • 12/11/24
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)Business Wire • 12/05/24
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development StrategyBusiness Wire • 12/03/24
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance OfficerBusiness Wire • 11/18/24
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts sayProactive Investors • 11/12/24
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business UpdateBusiness Wire • 10/24/24
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA TherapySeeking Alpha • 08/07/24